The combined MEK1/2-JAK2 inhibition (evaluated through Novartis inhibitors of MEK162 + NVP-BSK805) significantly reduced the tumor growth and enhanced the survival of tumor bearing mice, hence survival (Fig. 5a, b); however, the tumor started to resume while on treatment, suggesting a resistance phenotype. The gene discussed is JAK2; the disease is neoplasm.